Global Inactivated Vaccine Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Inactivated Vaccine market size was valued at USD 5983.1 million in 2023 and is forecast to a readjusted size of USD 7437.9 million by 2030 with a CAGR of 3.2% during review period.
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Inactivated Vaccine industry chain, the market status of Hospital (Children Inactivated Vaccine, Adult Inactivated Vaccine), Medical Center (Children Inactivated Vaccine, Adult Inactivated Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Inactivated Vaccine.
Regionally, the report analyzes the Inactivated Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Inactivated Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Inactivated Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Inactivated Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Children Inactivated Vaccine, Adult Inactivated Vaccine).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Inactivated Vaccine market.
Regional Analysis: The report involves examining the Inactivated Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Inactivated Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Inactivated Vaccine:
Company Analysis: Report covers individual Inactivated Vaccine players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Inactivated Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Medical Center).
Technology Analysis: Report covers specific technologies relevant to Inactivated Vaccine. It assesses the current state, advancements, and potential future developments in Inactivated Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Inactivated Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Inactivated Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Inactivated Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Inactivated Vaccine, with revenue, gross margin and global market share of Inactivated Vaccine from 2019 to 2024.
Chapter 3, the Inactivated Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Inactivated Vaccine market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Inactivated Vaccine.
Chapter 13, to describe Inactivated Vaccine research findings and conclusion.
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Inactivated Vaccine industry chain, the market status of Hospital (Children Inactivated Vaccine, Adult Inactivated Vaccine), Medical Center (Children Inactivated Vaccine, Adult Inactivated Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Inactivated Vaccine.
Regionally, the report analyzes the Inactivated Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Inactivated Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Inactivated Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Inactivated Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Children Inactivated Vaccine, Adult Inactivated Vaccine).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Inactivated Vaccine market.
Regional Analysis: The report involves examining the Inactivated Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Inactivated Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Inactivated Vaccine:
Company Analysis: Report covers individual Inactivated Vaccine players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Inactivated Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Medical Center).
Technology Analysis: Report covers specific technologies relevant to Inactivated Vaccine. It assesses the current state, advancements, and potential future developments in Inactivated Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Inactivated Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Inactivated Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Children Inactivated Vaccine
- Adult Inactivated Vaccine
- Hospital
- Medical Center
- Astellas Pharma(Japan)
- CSL Limited(Australia)
- Emergent BioSolutions(U.S.)
- GlaxoSmithKline(U.K.)
- Johnson & Johnson(U.S.)
- MedImmune(U.S.)
- Merck & Co(U.S.)
- Pfizer(U.S.)
- Sanofi Pasteur(France)
- Serum Institute of India Pvt(India)
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Inactivated Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Inactivated Vaccine, with revenue, gross margin and global market share of Inactivated Vaccine from 2019 to 2024.
Chapter 3, the Inactivated Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Inactivated Vaccine market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Inactivated Vaccine.
Chapter 13, to describe Inactivated Vaccine research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Inactivated Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Inactivated Vaccine by Type
1.3.1 Overview: Global Inactivated Vaccine Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Inactivated Vaccine Consumption Value Market Share by Type in 2023
1.3.3 Children Inactivated Vaccine
1.3.4 Adult Inactivated Vaccine
1.4 Global Inactivated Vaccine Market by Application
1.4.1 Overview: Global Inactivated Vaccine Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Medical Center
1.5 Global Inactivated Vaccine Market Size & Forecast
1.6 Global Inactivated Vaccine Market Size and Forecast by Region
1.6.1 Global Inactivated Vaccine Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Inactivated Vaccine Market Size by Region, (2019-2030)
1.6.3 North America Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.4 Europe Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.6 South America Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Inactivated Vaccine Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Astellas Pharma(Japan)
2.1.1 Astellas Pharma(Japan) Details
2.1.2 Astellas Pharma(Japan) Major Business
2.1.3 Astellas Pharma(Japan) Inactivated Vaccine Product and Solutions
2.1.4 Astellas Pharma(Japan) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Astellas Pharma(Japan) Recent Developments and Future Plans
2.2 CSL Limited(Australia)
2.2.1 CSL Limited(Australia) Details
2.2.2 CSL Limited(Australia) Major Business
2.2.3 CSL Limited(Australia) Inactivated Vaccine Product and Solutions
2.2.4 CSL Limited(Australia) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 CSL Limited(Australia) Recent Developments and Future Plans
2.3 Emergent BioSolutions(U.S.)
2.3.1 Emergent BioSolutions(U.S.) Details
2.3.2 Emergent BioSolutions(U.S.) Major Business
2.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Product and Solutions
2.3.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Emergent BioSolutions(U.S.) Recent Developments and Future Plans
2.4 GlaxoSmithKline(U.K.)
2.4.1 GlaxoSmithKline(U.K.) Details
2.4.2 GlaxoSmithKline(U.K.) Major Business
2.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Product and Solutions
2.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 GlaxoSmithKline(U.K.) Recent Developments and Future Plans
2.5 Johnson & Johnson(U.S.)
2.5.1 Johnson & Johnson(U.S.) Details
2.5.2 Johnson & Johnson(U.S.) Major Business
2.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Product and Solutions
2.5.4 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Johnson & Johnson(U.S.) Recent Developments and Future Plans
2.6 MedImmune(U.S.)
2.6.1 MedImmune(U.S.) Details
2.6.2 MedImmune(U.S.) Major Business
2.6.3 MedImmune(U.S.) Inactivated Vaccine Product and Solutions
2.6.4 MedImmune(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 MedImmune(U.S.) Recent Developments and Future Plans
2.7 Merck & Co(U.S.)
2.7.1 Merck & Co(U.S.) Details
2.7.2 Merck & Co(U.S.) Major Business
2.7.3 Merck & Co(U.S.) Inactivated Vaccine Product and Solutions
2.7.4 Merck & Co(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Merck & Co(U.S.) Recent Developments and Future Plans
2.8 Pfizer(U.S.)
2.8.1 Pfizer(U.S.) Details
2.8.2 Pfizer(U.S.) Major Business
2.8.3 Pfizer(U.S.) Inactivated Vaccine Product and Solutions
2.8.4 Pfizer(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pfizer(U.S.) Recent Developments and Future Plans
2.9 Sanofi Pasteur(France)
2.9.1 Sanofi Pasteur(France) Details
2.9.2 Sanofi Pasteur(France) Major Business
2.9.3 Sanofi Pasteur(France) Inactivated Vaccine Product and Solutions
2.9.4 Sanofi Pasteur(France) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Sanofi Pasteur(France) Recent Developments and Future Plans
2.10 Serum Institute of India Pvt(India)
2.10.1 Serum Institute of India Pvt(India) Details
2.10.2 Serum Institute of India Pvt(India) Major Business
2.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Product and Solutions
2.10.4 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Serum Institute of India Pvt(India) Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Inactivated Vaccine Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Inactivated Vaccine by Company Revenue
3.2.2 Top 3 Inactivated Vaccine Players Market Share in 2023
3.2.3 Top 6 Inactivated Vaccine Players Market Share in 2023
3.3 Inactivated Vaccine Market: Overall Company Footprint Analysis
3.3.1 Inactivated Vaccine Market: Region Footprint
3.3.2 Inactivated Vaccine Market: Company Product Type Footprint
3.3.3 Inactivated Vaccine Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Inactivated Vaccine Consumption Value and Market Share by Type (2019-2024)
4.2 Global Inactivated Vaccine Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Inactivated Vaccine Consumption Value Market Share by Application (2019-2024)
5.2 Global Inactivated Vaccine Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Inactivated Vaccine Consumption Value by Type (2019-2030)
6.2 North America Inactivated Vaccine Consumption Value by Application (2019-2030)
6.3 North America Inactivated Vaccine Market Size by Country
6.3.1 North America Inactivated Vaccine Consumption Value by Country (2019-2030)
6.3.2 United States Inactivated Vaccine Market Size and Forecast (2019-2030)
6.3.3 Canada Inactivated Vaccine Market Size and Forecast (2019-2030)
6.3.4 Mexico Inactivated Vaccine Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Inactivated Vaccine Consumption Value by Type (2019-2030)
7.2 Europe Inactivated Vaccine Consumption Value by Application (2019-2030)
7.3 Europe Inactivated Vaccine Market Size by Country
7.3.1 Europe Inactivated Vaccine Consumption Value by Country (2019-2030)
7.3.2 Germany Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.3 France Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.5 Russia Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.6 Italy Inactivated Vaccine Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Inactivated Vaccine Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Inactivated Vaccine Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Inactivated Vaccine Market Size by Region
8.3.1 Asia-Pacific Inactivated Vaccine Consumption Value by Region (2019-2030)
8.3.2 China Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.3 Japan Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.4 South Korea Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.5 India Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.7 Australia Inactivated Vaccine Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Inactivated Vaccine Consumption Value by Type (2019-2030)
9.2 South America Inactivated Vaccine Consumption Value by Application (2019-2030)
9.3 South America Inactivated Vaccine Market Size by Country
9.3.1 South America Inactivated Vaccine Consumption Value by Country (2019-2030)
9.3.2 Brazil Inactivated Vaccine Market Size and Forecast (2019-2030)
9.3.3 Argentina Inactivated Vaccine Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Inactivated Vaccine Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Inactivated Vaccine Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Inactivated Vaccine Market Size by Country
10.3.1 Middle East & Africa Inactivated Vaccine Consumption Value by Country (2019-2030)
10.3.2 Turkey Inactivated Vaccine Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Inactivated Vaccine Market Size and Forecast (2019-2030)
10.3.4 UAE Inactivated Vaccine Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Inactivated Vaccine Market Drivers
11.2 Inactivated Vaccine Market Restraints
11.3 Inactivated Vaccine Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Inactivated Vaccine Industry Chain
12.2 Inactivated Vaccine Upstream Analysis
12.3 Inactivated Vaccine Midstream Analysis
12.4 Inactivated Vaccine Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Inactivated Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Inactivated Vaccine by Type
1.3.1 Overview: Global Inactivated Vaccine Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Inactivated Vaccine Consumption Value Market Share by Type in 2023
1.3.3 Children Inactivated Vaccine
1.3.4 Adult Inactivated Vaccine
1.4 Global Inactivated Vaccine Market by Application
1.4.1 Overview: Global Inactivated Vaccine Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Medical Center
1.5 Global Inactivated Vaccine Market Size & Forecast
1.6 Global Inactivated Vaccine Market Size and Forecast by Region
1.6.1 Global Inactivated Vaccine Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Inactivated Vaccine Market Size by Region, (2019-2030)
1.6.3 North America Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.4 Europe Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.6 South America Inactivated Vaccine Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Inactivated Vaccine Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Astellas Pharma(Japan)
2.1.1 Astellas Pharma(Japan) Details
2.1.2 Astellas Pharma(Japan) Major Business
2.1.3 Astellas Pharma(Japan) Inactivated Vaccine Product and Solutions
2.1.4 Astellas Pharma(Japan) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Astellas Pharma(Japan) Recent Developments and Future Plans
2.2 CSL Limited(Australia)
2.2.1 CSL Limited(Australia) Details
2.2.2 CSL Limited(Australia) Major Business
2.2.3 CSL Limited(Australia) Inactivated Vaccine Product and Solutions
2.2.4 CSL Limited(Australia) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 CSL Limited(Australia) Recent Developments and Future Plans
2.3 Emergent BioSolutions(U.S.)
2.3.1 Emergent BioSolutions(U.S.) Details
2.3.2 Emergent BioSolutions(U.S.) Major Business
2.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Product and Solutions
2.3.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Emergent BioSolutions(U.S.) Recent Developments and Future Plans
2.4 GlaxoSmithKline(U.K.)
2.4.1 GlaxoSmithKline(U.K.) Details
2.4.2 GlaxoSmithKline(U.K.) Major Business
2.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Product and Solutions
2.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 GlaxoSmithKline(U.K.) Recent Developments and Future Plans
2.5 Johnson & Johnson(U.S.)
2.5.1 Johnson & Johnson(U.S.) Details
2.5.2 Johnson & Johnson(U.S.) Major Business
2.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Product and Solutions
2.5.4 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Johnson & Johnson(U.S.) Recent Developments and Future Plans
2.6 MedImmune(U.S.)
2.6.1 MedImmune(U.S.) Details
2.6.2 MedImmune(U.S.) Major Business
2.6.3 MedImmune(U.S.) Inactivated Vaccine Product and Solutions
2.6.4 MedImmune(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 MedImmune(U.S.) Recent Developments and Future Plans
2.7 Merck & Co(U.S.)
2.7.1 Merck & Co(U.S.) Details
2.7.2 Merck & Co(U.S.) Major Business
2.7.3 Merck & Co(U.S.) Inactivated Vaccine Product and Solutions
2.7.4 Merck & Co(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Merck & Co(U.S.) Recent Developments and Future Plans
2.8 Pfizer(U.S.)
2.8.1 Pfizer(U.S.) Details
2.8.2 Pfizer(U.S.) Major Business
2.8.3 Pfizer(U.S.) Inactivated Vaccine Product and Solutions
2.8.4 Pfizer(U.S.) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pfizer(U.S.) Recent Developments and Future Plans
2.9 Sanofi Pasteur(France)
2.9.1 Sanofi Pasteur(France) Details
2.9.2 Sanofi Pasteur(France) Major Business
2.9.3 Sanofi Pasteur(France) Inactivated Vaccine Product and Solutions
2.9.4 Sanofi Pasteur(France) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Sanofi Pasteur(France) Recent Developments and Future Plans
2.10 Serum Institute of India Pvt(India)
2.10.1 Serum Institute of India Pvt(India) Details
2.10.2 Serum Institute of India Pvt(India) Major Business
2.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Product and Solutions
2.10.4 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Serum Institute of India Pvt(India) Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Inactivated Vaccine Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Inactivated Vaccine by Company Revenue
3.2.2 Top 3 Inactivated Vaccine Players Market Share in 2023
3.2.3 Top 6 Inactivated Vaccine Players Market Share in 2023
3.3 Inactivated Vaccine Market: Overall Company Footprint Analysis
3.3.1 Inactivated Vaccine Market: Region Footprint
3.3.2 Inactivated Vaccine Market: Company Product Type Footprint
3.3.3 Inactivated Vaccine Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Inactivated Vaccine Consumption Value and Market Share by Type (2019-2024)
4.2 Global Inactivated Vaccine Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Inactivated Vaccine Consumption Value Market Share by Application (2019-2024)
5.2 Global Inactivated Vaccine Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Inactivated Vaccine Consumption Value by Type (2019-2030)
6.2 North America Inactivated Vaccine Consumption Value by Application (2019-2030)
6.3 North America Inactivated Vaccine Market Size by Country
6.3.1 North America Inactivated Vaccine Consumption Value by Country (2019-2030)
6.3.2 United States Inactivated Vaccine Market Size and Forecast (2019-2030)
6.3.3 Canada Inactivated Vaccine Market Size and Forecast (2019-2030)
6.3.4 Mexico Inactivated Vaccine Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Inactivated Vaccine Consumption Value by Type (2019-2030)
7.2 Europe Inactivated Vaccine Consumption Value by Application (2019-2030)
7.3 Europe Inactivated Vaccine Market Size by Country
7.3.1 Europe Inactivated Vaccine Consumption Value by Country (2019-2030)
7.3.2 Germany Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.3 France Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.5 Russia Inactivated Vaccine Market Size and Forecast (2019-2030)
7.3.6 Italy Inactivated Vaccine Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Inactivated Vaccine Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Inactivated Vaccine Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Inactivated Vaccine Market Size by Region
8.3.1 Asia-Pacific Inactivated Vaccine Consumption Value by Region (2019-2030)
8.3.2 China Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.3 Japan Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.4 South Korea Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.5 India Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Inactivated Vaccine Market Size and Forecast (2019-2030)
8.3.7 Australia Inactivated Vaccine Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Inactivated Vaccine Consumption Value by Type (2019-2030)
9.2 South America Inactivated Vaccine Consumption Value by Application (2019-2030)
9.3 South America Inactivated Vaccine Market Size by Country
9.3.1 South America Inactivated Vaccine Consumption Value by Country (2019-2030)
9.3.2 Brazil Inactivated Vaccine Market Size and Forecast (2019-2030)
9.3.3 Argentina Inactivated Vaccine Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Inactivated Vaccine Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Inactivated Vaccine Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Inactivated Vaccine Market Size by Country
10.3.1 Middle East & Africa Inactivated Vaccine Consumption Value by Country (2019-2030)
10.3.2 Turkey Inactivated Vaccine Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Inactivated Vaccine Market Size and Forecast (2019-2030)
10.3.4 UAE Inactivated Vaccine Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Inactivated Vaccine Market Drivers
11.2 Inactivated Vaccine Market Restraints
11.3 Inactivated Vaccine Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Inactivated Vaccine Industry Chain
12.2 Inactivated Vaccine Upstream Analysis
12.3 Inactivated Vaccine Midstream Analysis
12.4 Inactivated Vaccine Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Inactivated Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Inactivated Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Inactivated Vaccine Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Inactivated Vaccine Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Astellas Pharma(Japan) Company Information, Head Office, and Major Competitors
Table 6. Astellas Pharma(Japan) Major Business
Table 7. Astellas Pharma(Japan) Inactivated Vaccine Product and Solutions
Table 8. Astellas Pharma(Japan) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Astellas Pharma(Japan) Recent Developments and Future Plans
Table 10. CSL Limited(Australia) Company Information, Head Office, and Major Competitors
Table 11. CSL Limited(Australia) Major Business
Table 12. CSL Limited(Australia) Inactivated Vaccine Product and Solutions
Table 13. CSL Limited(Australia) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. CSL Limited(Australia) Recent Developments and Future Plans
Table 15. Emergent BioSolutions(U.S.) Company Information, Head Office, and Major Competitors
Table 16. Emergent BioSolutions(U.S.) Major Business
Table 17. Emergent BioSolutions(U.S.) Inactivated Vaccine Product and Solutions
Table 18. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Emergent BioSolutions(U.S.) Recent Developments and Future Plans
Table 20. GlaxoSmithKline(U.K.) Company Information, Head Office, and Major Competitors
Table 21. GlaxoSmithKline(U.K.) Major Business
Table 22. GlaxoSmithKline(U.K.) Inactivated Vaccine Product and Solutions
Table 23. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. GlaxoSmithKline(U.K.) Recent Developments and Future Plans
Table 25. Johnson & Johnson(U.S.) Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson(U.S.) Major Business
Table 27. Johnson & Johnson(U.S.) Inactivated Vaccine Product and Solutions
Table 28. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Johnson & Johnson(U.S.) Recent Developments and Future Plans
Table 30. MedImmune(U.S.) Company Information, Head Office, and Major Competitors
Table 31. MedImmune(U.S.) Major Business
Table 32. MedImmune(U.S.) Inactivated Vaccine Product and Solutions
Table 33. MedImmune(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. MedImmune(U.S.) Recent Developments and Future Plans
Table 35. Merck & Co(U.S.) Company Information, Head Office, and Major Competitors
Table 36. Merck & Co(U.S.) Major Business
Table 37. Merck & Co(U.S.) Inactivated Vaccine Product and Solutions
Table 38. Merck & Co(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Merck & Co(U.S.) Recent Developments and Future Plans
Table 40. Pfizer(U.S.) Company Information, Head Office, and Major Competitors
Table 41. Pfizer(U.S.) Major Business
Table 42. Pfizer(U.S.) Inactivated Vaccine Product and Solutions
Table 43. Pfizer(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Pfizer(U.S.) Recent Developments and Future Plans
Table 45. Sanofi Pasteur(France) Company Information, Head Office, and Major Competitors
Table 46. Sanofi Pasteur(France) Major Business
Table 47. Sanofi Pasteur(France) Inactivated Vaccine Product and Solutions
Table 48. Sanofi Pasteur(France) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Sanofi Pasteur(France) Recent Developments and Future Plans
Table 50. Serum Institute of India Pvt(India) Company Information, Head Office, and Major Competitors
Table 51. Serum Institute of India Pvt(India) Major Business
Table 52. Serum Institute of India Pvt(India) Inactivated Vaccine Product and Solutions
Table 53. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Serum Institute of India Pvt(India) Recent Developments and Future Plans
Table 55. Global Inactivated Vaccine Revenue (USD Million) by Players (2019-2024)
Table 56. Global Inactivated Vaccine Revenue Share by Players (2019-2024)
Table 57. Breakdown of Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Inactivated Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 59. Head Office of Key Inactivated Vaccine Players
Table 60. Inactivated Vaccine Market: Company Product Type Footprint
Table 61. Inactivated Vaccine Market: Company Product Application Footprint
Table 62. Inactivated Vaccine New Market Entrants and Barriers to Market Entry
Table 63. Inactivated Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Inactivated Vaccine Consumption Value (USD Million) by Type (2019-2024)
Table 65. Global Inactivated Vaccine Consumption Value Share by Type (2019-2024)
Table 66. Global Inactivated Vaccine Consumption Value Forecast by Type (2025-2030)
Table 67. Global Inactivated Vaccine Consumption Value by Application (2019-2024)
Table 68. Global Inactivated Vaccine Consumption Value Forecast by Application (2025-2030)
Table 69. North America Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 70. North America Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 71. North America Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 72. North America Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 73. North America Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 74. North America Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 75. Europe Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 76. Europe Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 77. Europe Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 78. Europe Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 79. Europe Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 80. Europe Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 81. Asia-Pacific Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 82. Asia-Pacific Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 83. Asia-Pacific Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 84. Asia-Pacific Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 85. Asia-Pacific Inactivated Vaccine Consumption Value by Region (2019-2024) & (USD Million)
Table 86. Asia-Pacific Inactivated Vaccine Consumption Value by Region (2025-2030) & (USD Million)
Table 87. South America Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 88. South America Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 89. South America Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 90. South America Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 91. South America Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 92. South America Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 93. Middle East & Africa Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 94. Middle East & Africa Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 95. Middle East & Africa Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 96. Middle East & Africa Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 97. Middle East & Africa Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 98. Middle East & Africa Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 99. Inactivated Vaccine Raw Material
Table 100. Key Suppliers of Inactivated Vaccine Raw Materials
Table 1. Global Inactivated Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Inactivated Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Inactivated Vaccine Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Inactivated Vaccine Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Astellas Pharma(Japan) Company Information, Head Office, and Major Competitors
Table 6. Astellas Pharma(Japan) Major Business
Table 7. Astellas Pharma(Japan) Inactivated Vaccine Product and Solutions
Table 8. Astellas Pharma(Japan) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Astellas Pharma(Japan) Recent Developments and Future Plans
Table 10. CSL Limited(Australia) Company Information, Head Office, and Major Competitors
Table 11. CSL Limited(Australia) Major Business
Table 12. CSL Limited(Australia) Inactivated Vaccine Product and Solutions
Table 13. CSL Limited(Australia) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. CSL Limited(Australia) Recent Developments and Future Plans
Table 15. Emergent BioSolutions(U.S.) Company Information, Head Office, and Major Competitors
Table 16. Emergent BioSolutions(U.S.) Major Business
Table 17. Emergent BioSolutions(U.S.) Inactivated Vaccine Product and Solutions
Table 18. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Emergent BioSolutions(U.S.) Recent Developments and Future Plans
Table 20. GlaxoSmithKline(U.K.) Company Information, Head Office, and Major Competitors
Table 21. GlaxoSmithKline(U.K.) Major Business
Table 22. GlaxoSmithKline(U.K.) Inactivated Vaccine Product and Solutions
Table 23. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. GlaxoSmithKline(U.K.) Recent Developments and Future Plans
Table 25. Johnson & Johnson(U.S.) Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson(U.S.) Major Business
Table 27. Johnson & Johnson(U.S.) Inactivated Vaccine Product and Solutions
Table 28. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Johnson & Johnson(U.S.) Recent Developments and Future Plans
Table 30. MedImmune(U.S.) Company Information, Head Office, and Major Competitors
Table 31. MedImmune(U.S.) Major Business
Table 32. MedImmune(U.S.) Inactivated Vaccine Product and Solutions
Table 33. MedImmune(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. MedImmune(U.S.) Recent Developments and Future Plans
Table 35. Merck & Co(U.S.) Company Information, Head Office, and Major Competitors
Table 36. Merck & Co(U.S.) Major Business
Table 37. Merck & Co(U.S.) Inactivated Vaccine Product and Solutions
Table 38. Merck & Co(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Merck & Co(U.S.) Recent Developments and Future Plans
Table 40. Pfizer(U.S.) Company Information, Head Office, and Major Competitors
Table 41. Pfizer(U.S.) Major Business
Table 42. Pfizer(U.S.) Inactivated Vaccine Product and Solutions
Table 43. Pfizer(U.S.) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Pfizer(U.S.) Recent Developments and Future Plans
Table 45. Sanofi Pasteur(France) Company Information, Head Office, and Major Competitors
Table 46. Sanofi Pasteur(France) Major Business
Table 47. Sanofi Pasteur(France) Inactivated Vaccine Product and Solutions
Table 48. Sanofi Pasteur(France) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Sanofi Pasteur(France) Recent Developments and Future Plans
Table 50. Serum Institute of India Pvt(India) Company Information, Head Office, and Major Competitors
Table 51. Serum Institute of India Pvt(India) Major Business
Table 52. Serum Institute of India Pvt(India) Inactivated Vaccine Product and Solutions
Table 53. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Serum Institute of India Pvt(India) Recent Developments and Future Plans
Table 55. Global Inactivated Vaccine Revenue (USD Million) by Players (2019-2024)
Table 56. Global Inactivated Vaccine Revenue Share by Players (2019-2024)
Table 57. Breakdown of Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Inactivated Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 59. Head Office of Key Inactivated Vaccine Players
Table 60. Inactivated Vaccine Market: Company Product Type Footprint
Table 61. Inactivated Vaccine Market: Company Product Application Footprint
Table 62. Inactivated Vaccine New Market Entrants and Barriers to Market Entry
Table 63. Inactivated Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Inactivated Vaccine Consumption Value (USD Million) by Type (2019-2024)
Table 65. Global Inactivated Vaccine Consumption Value Share by Type (2019-2024)
Table 66. Global Inactivated Vaccine Consumption Value Forecast by Type (2025-2030)
Table 67. Global Inactivated Vaccine Consumption Value by Application (2019-2024)
Table 68. Global Inactivated Vaccine Consumption Value Forecast by Application (2025-2030)
Table 69. North America Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 70. North America Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 71. North America Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 72. North America Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 73. North America Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 74. North America Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 75. Europe Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 76. Europe Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 77. Europe Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 78. Europe Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 79. Europe Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 80. Europe Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 81. Asia-Pacific Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 82. Asia-Pacific Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 83. Asia-Pacific Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 84. Asia-Pacific Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 85. Asia-Pacific Inactivated Vaccine Consumption Value by Region (2019-2024) & (USD Million)
Table 86. Asia-Pacific Inactivated Vaccine Consumption Value by Region (2025-2030) & (USD Million)
Table 87. South America Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 88. South America Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 89. South America Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 90. South America Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 91. South America Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 92. South America Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 93. Middle East & Africa Inactivated Vaccine Consumption Value by Type (2019-2024) & (USD Million)
Table 94. Middle East & Africa Inactivated Vaccine Consumption Value by Type (2025-2030) & (USD Million)
Table 95. Middle East & Africa Inactivated Vaccine Consumption Value by Application (2019-2024) & (USD Million)
Table 96. Middle East & Africa Inactivated Vaccine Consumption Value by Application (2025-2030) & (USD Million)
Table 97. Middle East & Africa Inactivated Vaccine Consumption Value by Country (2019-2024) & (USD Million)
Table 98. Middle East & Africa Inactivated Vaccine Consumption Value by Country (2025-2030) & (USD Million)
Table 99. Inactivated Vaccine Raw Material
Table 100. Key Suppliers of Inactivated Vaccine Raw Materials
LIST OF FIGURES
Figure 1. Inactivated Vaccine Picture
Figure 2. Global Inactivated Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Inactivated Vaccine Consumption Value Market Share by Type in 2023
Figure 4. Children Inactivated Vaccine
Figure 5. Adult Inactivated Vaccine
Figure 6. Global Inactivated Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Inactivated Vaccine Consumption Value Market Share by Application in 2023
Figure 8. Hospital Picture
Figure 9. Medical Center Picture
Figure 10. Global Inactivated Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global Inactivated Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Market Inactivated Vaccine Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 13. Global Inactivated Vaccine Consumption Value Market Share by Region (2019-2030)
Figure 14. Global Inactivated Vaccine Consumption Value Market Share by Region in 2023
Figure 15. North America Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 16. Europe Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 17. Asia-Pacific Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 18. South America Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 19. Middle East and Africa Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 20. Global Inactivated Vaccine Revenue Share by Players in 2023
Figure 21. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 22. Global Top 3 Players Inactivated Vaccine Market Share in 2023
Figure 23. Global Top 6 Players Inactivated Vaccine Market Share in 2023
Figure 24. Global Inactivated Vaccine Consumption Value Share by Type (2019-2024)
Figure 25. Global Inactivated Vaccine Market Share Forecast by Type (2025-2030)
Figure 26. Global Inactivated Vaccine Consumption Value Share by Application (2019-2024)
Figure 27. Global Inactivated Vaccine Market Share Forecast by Application (2025-2030)
Figure 28. North America Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 29. North America Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 30. North America Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 31. United States Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 32. Canada Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 33. Mexico Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 34. Europe Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 35. Europe Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 36. Europe Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 37. Germany Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 38. France Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 39. United Kingdom Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 40. Russia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 41. Italy Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 42. Asia-Pacific Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 43. Asia-Pacific Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 44. Asia-Pacific Inactivated Vaccine Consumption Value Market Share by Region (2019-2030)
Figure 45. China Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 46. Japan Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 47. South Korea Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 48. India Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 49. Southeast Asia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 50. Australia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 51. South America Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 52. South America Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 53. South America Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 54. Brazil Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 55. Argentina Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 56. Middle East and Africa Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 57. Middle East and Africa Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 58. Middle East and Africa Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 59. Turkey Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 60. Saudi Arabia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 61. UAE Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 62. Inactivated Vaccine Market Drivers
Figure 63. Inactivated Vaccine Market Restraints
Figure 64. Inactivated Vaccine Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Inactivated Vaccine in 2023
Figure 67. Manufacturing Process Analysis of Inactivated Vaccine
Figure 68. Inactivated Vaccine Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Figure 1. Inactivated Vaccine Picture
Figure 2. Global Inactivated Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Inactivated Vaccine Consumption Value Market Share by Type in 2023
Figure 4. Children Inactivated Vaccine
Figure 5. Adult Inactivated Vaccine
Figure 6. Global Inactivated Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Inactivated Vaccine Consumption Value Market Share by Application in 2023
Figure 8. Hospital Picture
Figure 9. Medical Center Picture
Figure 10. Global Inactivated Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global Inactivated Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Market Inactivated Vaccine Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 13. Global Inactivated Vaccine Consumption Value Market Share by Region (2019-2030)
Figure 14. Global Inactivated Vaccine Consumption Value Market Share by Region in 2023
Figure 15. North America Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 16. Europe Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 17. Asia-Pacific Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 18. South America Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 19. Middle East and Africa Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 20. Global Inactivated Vaccine Revenue Share by Players in 2023
Figure 21. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 22. Global Top 3 Players Inactivated Vaccine Market Share in 2023
Figure 23. Global Top 6 Players Inactivated Vaccine Market Share in 2023
Figure 24. Global Inactivated Vaccine Consumption Value Share by Type (2019-2024)
Figure 25. Global Inactivated Vaccine Market Share Forecast by Type (2025-2030)
Figure 26. Global Inactivated Vaccine Consumption Value Share by Application (2019-2024)
Figure 27. Global Inactivated Vaccine Market Share Forecast by Application (2025-2030)
Figure 28. North America Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 29. North America Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 30. North America Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 31. United States Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 32. Canada Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 33. Mexico Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 34. Europe Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 35. Europe Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 36. Europe Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 37. Germany Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 38. France Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 39. United Kingdom Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 40. Russia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 41. Italy Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 42. Asia-Pacific Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 43. Asia-Pacific Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 44. Asia-Pacific Inactivated Vaccine Consumption Value Market Share by Region (2019-2030)
Figure 45. China Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 46. Japan Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 47. South Korea Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 48. India Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 49. Southeast Asia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 50. Australia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 51. South America Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 52. South America Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 53. South America Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 54. Brazil Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 55. Argentina Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 56. Middle East and Africa Inactivated Vaccine Consumption Value Market Share by Type (2019-2030)
Figure 57. Middle East and Africa Inactivated Vaccine Consumption Value Market Share by Application (2019-2030)
Figure 58. Middle East and Africa Inactivated Vaccine Consumption Value Market Share by Country (2019-2030)
Figure 59. Turkey Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 60. Saudi Arabia Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 61. UAE Inactivated Vaccine Consumption Value (2019-2030) & (USD Million)
Figure 62. Inactivated Vaccine Market Drivers
Figure 63. Inactivated Vaccine Market Restraints
Figure 64. Inactivated Vaccine Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Inactivated Vaccine in 2023
Figure 67. Manufacturing Process Analysis of Inactivated Vaccine
Figure 68. Inactivated Vaccine Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
